AMERICAN SOCIETY OF CLINICAL ONCOLOGY for AMERICAN SOCIETY OF CLINICAL ONCOLOGY
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 717, 21st Century Cancer ALERT Act S. 488/H.R. 716, Access to Cancer Clinical Trials Act H.R. 1548, the Pathway for Biosimilars Act H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act General discussion on draft language for childhood cancer survivorship General discussion on draft language for comprehensive care planning
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT BLACKWELL New | Special Assistant, Rep. Joe Schwarz, 2005-2006 |
| SHELAGH FOSTER New | — |
Medicare/Medicaid MMM
H.R. 1392, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program Medicare Reimbursement for Chemotherapy Drugs Medicare Coverage of Clinical Trials
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT BLACKWELL | Special Assistant, Rep. Joe Schwarz, 2005-2006 |
| SHELAGH FOSTER | — |
Budget/Appropriations BUD
H.R. 1, The American Recovery and Reinvestment Act H.R. 1105, FY 2009 Omnibus Appropriations Act General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT BLACKWELL | Special Assistant, Rep. Joe Schwarz, 2005-2006 |
| SHELAGH FOSTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.